Spyre Therapeutics (SYRE) Other Non-Current Liabilities (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Other Non-Current Liabilities data on file, last reported at $57.0 million in Q1 2026.

• Quarterly Other Non-Current Liabilities rose 245.36% year-over-year to $57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.0 million (up 245.36% YoY) and the FY2024 annual result came in at $36.6 million, down 11.35% from the prior year.
• Other Non-Current Liabilities advanced to $57.0 million in Q1 2026, from $3.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $164.4 million in Q2 2023 to a low of $8000.0 in Q1 2022.
• A 5-year average of $41.3 million and a median of $36.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 96.12% — and 2026, when it surged 245.36%.
• Tracing SYRE's Other Non-Current Liabilities over 5 years: stood at $8000.0 in 2022, then soared by 516275.0% to $41.3 million in 2023, then decreased by 11.35% to $36.6 million in 2024, then tumbled by 91.18% to $3.2 million in 2025, then surged by 1663.16% to $57.0 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $57.0 million (Q1 2026), $3.2 million (Q3 2025), and $16.5 million (Q1 2025), per Business Quant data.